Inicio › Cáncer de pulmón › Virginia

Ensayos clínicos de Cáncer de pulmón en Virginia

57 estudios sobre Cáncer de pulmón buscan participantes en Virginia.

Ciudades en Virginia

Texto oficial del estudio (inglés)

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Virginia Cancer Specialists, Fairfax

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06765109

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Ballad Health Cancer Care - Bristol, Bristol
Augusta Health Center for Cancer and Blood Disorders, Fishersville
Centra Alan B Pearson Regional Cancer Center, Lynchburg
y 7 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT04267848

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

VCU Massey Cancer Center at Stony Point, Richmond
VCU Massey Comprehensive Cancer Center, Richmond
VCU Community Memorial Health Center, South Hill
y 1 más

ReclutandoFase 3

Edades de 70 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

University of Virginia Cancer Center, Charlottesville

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT04181060

A Study of PHN-012 in Patients With Advanced Solid Tumors

PHN-012-001 Site, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07127874

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Virginia Cancer Specialists, Fairfax

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06881784

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
Centra Alan B Pearson Regional Cancer Center, Lynchburg
Virginia Cancer Institute, Richmond
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06498635

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Inova Schar Cancer Infusion Pharmacy, Fairfax
Inova Schar Cancer, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07519655

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

UVA Comprehensive Cancer Center, Charlottesville
UVA Health Fontaine Research Park, Charlottesville
University of Virginia, Charlottesville
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07222566

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Fairfax

ReclutandoFase 2

Edades de 18 a 95 · Todos los sexos · Actualizado el 23 sept 2026 · NCT05061550

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Virginia Commonwealth University, Richmond

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07063745

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NEXT Oncology Virginia, Fairfax

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

University of Virginia Health System, Charlottesville
Virginia Commonwealth University (Vcu), Richmond

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07100080

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Virginia Cancer Specialists - Arlington, Arlington
Virginia Cancer Specialists, Fairfax
VCU Massey Cancer Center, Richmond
y 1 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06712316

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Next Oncology Virginia Cancer Specialist, Fairfax

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07629960

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

Virginia Cancer Specialists, Fairfax

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07625644

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

University of Virginia Cancer Center, Charlottesville
VCU Massey Comprehensive Cancer Center, Richmond

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT06287775

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NEXT - Virginia, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07349537

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NEXT Virginia, Fairfax

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT05786924

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Virginia Cancer Specialists, Fairfax

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04585750

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Virginia Cancer Specialists, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06293898

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Virginia Oncology Associates, Norfolk

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

University of Virginia Health System, Charlottesville
USO - Virginia Cancer Specialists, Fairfax
VCU Health Adult Outpatient Pavillion, Richmond

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06119581

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

USO-Virginia Cancer Specialists, PC, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06561685

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

University of Virginia Cancer Center, Charlottesville

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07012031

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Avenzo Therapeutics Recruiting Site, Fairfax

ReclutandoFase 1/2

Edades de 18 a 75 · Todos los sexos · Actualizado el 4 sept 2026 · NCT07038343

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NEXT Oncology, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06343402

The Vanguard Study: Testing a New Way to Screen for Cancer

Sentara Martha Jefferson Hospital, Charlottesville
Inova Schar Cancer Institute, Fairfax
Inova Fair Oaks Hospital, Fairfax
y 5 más

ReclutandoSe aceptan voluntarios sanos

Edades de 45 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT06995898

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Chesapeake Regional Medical Center, Chesapeake
Augusta Health Center for Cancer and Blood Disorders, Fishersville
Bon Secours Memorial Regional Medical Center, Mechanicsville
y 7 más

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

University of Virginia, Charlottesville
Virginia Cancer Specialists, Fairfax
Shenandoah Oncology, P.C., Winchester

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 sept 2026 · NCT07185997

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Virginia Cancer Specialists, Fairfax
Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg
Virginia Commonwealth University School of Medicine, Richmond
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 sept 2026 · NCT06712355

Health Education Approach to Lung Screening

Virginia Commonwealth University, Richmond

ReclutandoSe aceptan voluntarios sanos

Edades de 50 a 80 · Todos los sexos · Actualizado el 25 ago 2026 · NCT06070870

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Inova Alexandria Hospital, Alexandria
Inova Schar Cancer Institute, Fairfax
Inova Fair Oaks Hospital, Fairfax
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT06500481

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

NEXT Oncology - Virginia Cancer Specialists, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT07444814

Empathic Communication Skills (ECS) Training

Chesapeake Regional Healthcare (Data Collection Only), Chesapeake

ReclutandoSe aceptan voluntarios sanos

Edades de 18 a 100 · Todos los sexos · Actualizado el 23 jul 2026 · NCT05456841

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NEXT Virginia, Fairfax

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jul 2026 · NCT05652686

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

NEXT Virginia, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 jul 2026 · NCT07315113

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NEXT Oncology Virginia, Fairfax

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 jun 2026 · NCT06162221

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

NEXT Virginia, Fairfax

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT07458347

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

VCU Medical Center (Virginia Commonwealth University), Richmond

ReclutandoFase 2

Edades de 18 a 70 · Todos los sexos · Actualizado el 26 jun 2026 · NCT04614103

De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.